Compare Eli Lilly And Co (LLY) vs NetFlix Inc (NFLX) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Netflix (NFLX) trades at $76.29, up 2.9% in the last session, showing resilience amid recent volatility. The stock exhibits bullish technical signals with strong moving average alignment, though RSI levels suggest potential overbought conditions near-term. Fundamentally, Netflix demonstrates robust growth with Q1 2026 EPS beating expectations at $1.23 versus $0.763, and revenue climbing to $45.18 billion in 2025. Operating cash flow surged to $10.15 billion, underscoring financial health. The company's expansion into advertising and live sports is viewed positively by analysts.

Outlook remains favorable with a consensus price target of $90.45, implying ~19% upside, supported by 64% analyst buy ratings. Key opportunities include ad-tier monetization and global content leadership. Risks involve competitive pressures from streaming rivals, execution on new initiatives, and market sentiment shifts. The stock's current valuation at P/E 23.52 appears reasonable given earnings growth trajectory, but investors should monitor quarterly execution against high expectations.